Cargando…

Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study

A randomized clinical trial showed that trastuzumab, added to traditional chemotherapy, significantly improved overall survival in human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric cancer patients. This population-based study aimed at evaluating both the clinical and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franchi, Matteo, Tritto, Roberta, Torroni, Lorena, Reno, Chiara, La Vecchia, Carlo, Corrao, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352495/ https://www.ncbi.nlm.nih.gov/pubmed/32630517 http://dx.doi.org/10.3390/cancers12061691

Ejemplares similares

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
por: Franchi, Matteo, et al.
Publicado: (2020)

Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2021)

Treatment Patterns, Clinical Outcomes and Healthcare Costs of Advanced Non-Small Cell Lung Cancer: A Real-World Evaluation in Italy
por: Franchi, Matteo, et al.
Publicado: (2021)

Healthcare Services for Undocumented Migrants: Organisation and Costs from the Italian NHS Perspective
por: Listorti, Elisabetta, et al.
Publicado: (2022)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Effects of SARS-CoV-2 pandemic on follow-up and pharmacological treatment of chronic diseases in undocumented migrants
por: Fiorini, Gianfrancesco, et al.
Publicado: (2021)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Impact of the First and Second Lockdown for COVID-19 Pandemic on Preterm Birth, Low Birth Weight, Stillbirth, Mode of Labor, and of Delivery in Lombardy, Italy
por: Esposito, Giovanna, et al.
Publicado: (2023)

Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2020)

Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
por: Vera-Llonch, Montserrat, et al.
Publicado: (2011)

Change in healthcare during Covid-19 pandemic was assessed through observational designs
por: Corrao, Giovanni, et al.
Publicado: (2022)

Obstetric and neonatal outcomes in women with pregnancy associated cancer: a population-based study in Lombardy, Northern Italy
por: Esposito, Giovanna, et al.
Publicado: (2021)

Spontaneous and induced abortions in women with a diagnosis of gestational related neoplasm: a population-based linkage study in Lombardy, 2010–2020
por: Esposito, Giovanna, et al.
Publicado: (2023)

Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Schneider, Jean, et al.
Publicado: (2020)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD
por: Ronco, Raffaella, et al.
Publicado: (2023)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy
por: Ha, Gi-Young, et al.
Publicado: (2020)

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2019)

Dilated cardiomyopathy following trastuzumab chemotherapy
por: Karmakar, Saurabh, et al.
Publicado: (2012)

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
por: Vera-Llonch, Montserrat, et al.
Publicado: (2011)

Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
por: Hannouf, Malek B., et al.
Publicado: (2012)

Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
por: Zhang, Yanqiang, et al.
Publicado: (2022)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Knocking on heaven's door: The gap between health institutions and academies in generating knowledge utilizing real-world data
por: Corrao, Giovanni, et al.
Publicado: (2022)

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
por: Disel, Umut, et al.
Publicado: (2015)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
por: Aitelhaj, Meryem, et al.
Publicado: (2016)

Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Jitawatanarat, Potjana, et al.
Publicado: (2014)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
por: Chen, Zhe-Ling, et al.
Publicado: (2016)

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2022)

Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study
por: Bengala, C, et al.
Publicado: (2006)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
por: Ong, Siew Chin, et al.
Publicado: (2023)

Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hgop5gesp2hn2sq31oip28ktg9